Aquestive Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.9%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$0.42next fiscal year
Monitoring Framework
Key Performance Indicators
Total Revenues Quarterly14.5MTarget: 46000000 to 50000000
Non-GAAP Adjusted EBITDA Loss AnnuallyTarget: -30000000 to -35000000
Watch Items
- Anaphylm NDA ResubmissionTrigger: NDA resubmission to the FDAAction: Monitor for completion of the human factors validation study and PK study to support resubmission in Q3 2026.
- Cash Runway and LiquidityTrigger: Cash balance below $50 millionAction: Evaluate cash burn rate and potential non-dilutive funding drawdowns, such as the $75 million RTW Investments agreement upon Anaphylm approval.
Research as of 19 Jun 2026